<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461068</url>
  </required_header>
  <id_info>
    <org_study_id>H16-01846</org_study_id>
    <nct_id>NCT03461068</nct_id>
  </id_info>
  <brief_title>Exogenous Ketones and Glucose Tolerance</brief_title>
  <official_title>The Effect of Exogenous Ketone Monoester Supplement on Glycemic Response to an Oral Glucose Tolerance Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ketone body beta-hydroxybutyrate is produced during prolonged fasting or when endogenous
      carbohydrate stores are depleted and can be used as an alternative fuel source. Exogenous
      beta-hydroxybutyrate, in the form of a ketone monoester, is proposed to have glucose-lowering
      potential but this has not been adequately studied. The purpose of this study is to determine
      whether supplementing with an acute dose of ketone monoester can improve the glycemic
      response to an oral glucose tolerance test in individuals with impaired fasting glucose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Placebo masked with flavouring and participants consume in opaque containers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>Area under the curve for glucose during oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>Insulin area under the curve during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>Non-esterified fatty acids area under the curve during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caspase-1 activation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Caspase-1 activation assessed before and after ketone or placebo ingestion in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines</measure>
    <time_frame>15 minutes</time_frame>
    <description>Inflammatory cytokines assessed before and after ketone or placebo ingestion in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>C-peptide area under the curve during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>GLP-1 area under the curve during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>Glucagon area under the curve during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose incremental area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>Incremental area under the curve (above baseline) for glucose during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin incremental area under the curve</measure>
    <time_frame>2-hour</time_frame>
    <description>Incremental area under the curve (above baseline) for insulin during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hr glucose level</measure>
    <time_frame>2-hour</time_frame>
    <description>Plasma glucose assessed 2-hr after oral glucose tolerance test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral glucose sensitivity index</measure>
    <time_frame>2-hour</time_frame>
    <description>Oral glucose sensitivity index derived from glucose and insulin values throughout the 2-hr oral glucose tolerance test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Ketones</condition>
  <condition>Dietary Supplements</condition>
  <arm_group>
    <arm_group_label>Ketone monoester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acute morning dose of flavour-matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone monoester</intervention_name>
    <description>Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.</description>
    <arm_group_label>Ketone monoester</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not taking any medications affecting glucose metabolism.

          -  Elevated fasting glucose level (5.6-6.9 mmol/L).

        Exclusion Criteria:

          -  Diagnosed with diabetes.

          -  Diagnosed with heart disease.

          -  Competitive endurance athlete (self-identified as engaged in specific endurance
             training in triathlon, cycling, or distance running and competing in races or
             competition)

          -  Recent (last 3 months) or current consumption of a low-carbohydrate ketogenic diet

          -  Current consumption of ketone supplements

          -  Pregnant or planning to become pregnant during the study (if female)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan P Little, PhD</last_name>
    <phone>2508079876</phone>
    <email>jonathan.little@ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of British Columbia, Okanagan.</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1V 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan P Little, PHD</last_name>
      <phone>+12508786893</phone>
      <email>jonathan.little@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Étienne Myette-Côté, MSC</last_name>
      <phone>250 807 9122</phone>
      <email>myettect@ualberta.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jonathan Little</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

